Felodipine
- Generic Name
- Felodipine
- Brand Names
- Plendil
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19Cl2NO4
- CAS Number
- 72509-76-3
- Unique Ingredient Identifier
- OL961R6O2C
- Background
Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension.
- Indication
For the treatment of mild to moderate essential hypertension.
- Associated Conditions
- Hypertension
Felodipine Controlled Release Tablets and Felodipine Sustained Release Tablets in Healthy Subjects Under Fasting State Comparative Pharmacokinetic Study
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Overseas Pharmaceuticals, Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05614037
- Locations
- 🇨🇳
Clinical Trial Centre of Dongguan Kanghua Hospital, Dongguan, Guangdong, China
Copenhagen Acute Renal Complications After Transplantations Study Group
- Conditions
- Disorder Related to Lung Transplantation
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 42
- Registration Number
- NCT02744872
- Locations
- 🇩🇰
Department of Nephrology P, Copenhagen University Hospital, Rigshospitalet, Copenhagen Ø, Copenhagen, Denmark
The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 529
- Registration Number
- NCT02336607
Bioequivalence Study of Felodipine ER Tablets 10 mg Under Fasting Conditions
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Ranbaxy Laboratories Limited
- Target Recruit Count
- 48
- Registration Number
- NCT02327247
Bioequivalence Study of Felodipine ER Tablets 10 mg Under Fed Conditions
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- Ranbaxy Laboratories Limited
- Target Recruit Count
- 80
- Registration Number
- NCT02311530
Coffee Interaction With the Antihypertensive Drug Felodipine
- Conditions
- Food-Drug Interactions
- Interventions
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 13
- Registration Number
- NCT02232269
- Locations
- 🇨🇦
Victoria Clinical Trials Centre, London, Ontario, Canada
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fed Condition
- Conditions
- Healthy
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Registration Number
- NCT01630902
- Locations
- 🇮🇳
Bio Evaluation Centre, Torrent Pharmaceuticals Ltd., Village Bhat, Gandhinagar, Gujarat, India
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fasting Condition
- Conditions
- Healthy
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Registration Number
- NCT01630655
- Locations
- 🇮🇳
AXIS Clinicals Limited(formerly Trident Life Sciences Ltd.), Miyapur, Hyderabad, India
Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2014-10-16
- Lead Sponsor
- Lee's Pharmaceutical Limited
- Target Recruit Count
- 281
- Registration Number
- NCT01520285
- Locations
- 🇨🇳
Shanghai First People's Hospital, Shanghai, China
Combined Antihypertensive Therapy and Sexual Dysfunction
- Conditions
- HypertensionSexual Dysfunction
- Interventions
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2010-11-11
- Lead Sponsor
- LanZhou University
- Target Recruit Count
- 280
- Registration Number
- NCT01238705
- Locations
- 🇨🇳
The Second Hospital of Lanzhou University, Lanzhou, Gansu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.